Recommendation Strength Guide

# Recommendation Strength Guide ## GRADE Framework for Clinical Recommendations ### Components of a Recommendation Every clinical recommendation should address: 1. **Population**: Who should receive the intervention? 2. **Intervention**: What specific treatment/action? 3. **Comparator**: Compared to what alternative? 4. **Outcome**: What are the expected results? 5. **Strength**: How strong is the recommendation? 6. **Quality of Evidence**: How confident are we in the evidence? ### Recommendation Strength (Grade 1 vs Grade 2) #### Strong Recommendation (Grade 1) **When to Use**: - Desirable effects clearly outweigh undesirable effects (or vice versa) - High or moderate quality evidence - Values and preferences: Little variability expected - Resource implications: Cost-effective or cost considerations minor **Wording**: "We recommend..." or "Clinicians should..." **Implications**: - Most patients should receive the recommended intervention - Adherence to recommendation could be a quality indicator - Policy-makers can adapt as performance measure **Examples**: ``` STRONG RECOMMENDATION FOR (Grade 1): "We recommend osimertinib 80 mg daily as first-line therapy for adults with advanced NSCLC harboring EGFR exon 19 deletion or L858R mutation (Strong recommendation, High-quality evidence - GRADE 1A)." Rationale: - Large PFS benefit: 18.9 vs 10.2 months (HR 0.46, p5 or <0.2) - Low quality evidence, but clear benefit-harm balance - Example: Anticoagulation for atrial fibrillation (before RCTs, strong observational data) **Weak Recommendation with High Quality Evidence (Grade 2A)** Occurs when: - Benefits and harms closely balanced - Patient values highly variable - Example: Aspirin for primary prevention in low-risk individuals (benefits small, bleeding risk present, patient values vary) ## Wording Templates ### Strong Recommendations **FOR (↑↑)**: - "We recommend [intervention] for [population]." - "Clinicians should [action]." - "[Intervention] is recommended." **AGAINST (↓↓)**: - "We recommend against [intervention] for [population]." - "Clinicians should not [action]." - "[Intervention] is not recommended." ### Conditional/Weak Recommendations **FOR (↑)**: - "We suggest [intervention] for [population]." - "Clinicians might consider [action]." - "[Intervention] may be considered for selected patients." **AGAINST (↓)**: - "We suggest not using [intervention] for [population]." - "Clinicians might avoid [action]." - "[Intervention] is generally not recommended." **EITHER ACCEPTABLE**: - "We suggest either [option A] or [option B] based on patient preferences." - "Either approach is reasonable." ## Color Coding for Visual Documents **Strong Recommendations (Green Background)**: - RGB(0, 153, 76) or #009954 - Clear visual priority - Use for Grade 1A, 1B **Conditional Recommendations (Yellow Background)**: - RGB(255, 193, 7) or #FFC107 - Indicates discussion needed - Use for Grade 2A, 2B, 2C **Research/Investigational (Blue Background)**: - RGB(33, 150, 243) or #2196F3 - Clinical trial consideration - Insufficient evidence for standard care **Not Recommended (Red Border/Background)**: - RGB(220, 20, 60) or #DC143C - Strong recommendation against - Evidence of harm or no benefit ## Common Scenarios ### Scenario 1: Strong Evidence, Clear Benefit-Harm Balance **Example**: Pembrolizumab for PD-L1 ≥50% NSCLC - Evidence: Large phase 3 RCT (KEYNOTE-024), n=305, well-designed - Results: PFS HR 0.50 (0.37-0.68), OS HR 0.60 (0.41-0.89) - Toxicity: Lower grade 3-5 AEs than chemotherapy (27% vs 53%) - Patient values: Most prioritize efficacy and tolerability **Recommendation**: STRONG FOR (Grade 1A) ### Scenario 2: Moderate Evidence, Balanced Trade-Offs **Example**: Adjuvant immunotherapy for resected melanoma - Evidence: RCT showing relapse-free survival benefit, OS data immature - Results: Recurrence risk reduced but ongoing toxicity - Toxicity: Immune-related AEs requiring steroids (some severe) - Cost: High annual cost for 12 months treatment - Patient values: Variable (some prioritize recurrence prevention, others avoid toxicity) **Recommendation**: CONDITIONAL FOR (Grade 2B) ### Scenario 3: Low Evidence, but Severe Consequence **Example**: Anticoagulation for prosthetic heart valve - Evidence: No RCTs (would be unethical), observational data and mechanistic reasoning - Consequence: Very high thromboembolic risk without anticoagulation - Benefit-harm: Clear despite low quality evidence **Recommendation**: STRONG FOR (Grade 1C) ### Scenario 4: High Evidence, but Patient Preferences Vary **Example**: Breast reconstruction after mastectomy - Evidence: High-quality data on outcomes and satisfaction - Trade-offs: Cosmetic benefit vs additional surgery, recovery time - Values: Highly personal decision, wide preference variability **Recommendation**: CONDITIONAL (Grade 2A) - discuss options, patient decides ## Documentation Template ``` RECOMMENDATION: [State recommendation clearly] Strength: [STRONG / CONDITIONAL] Quality of Evidence: [HIGH / MODERATE / LOW / VERY LOW] GRADE: [1A / 1B / 2A / 2B / 2C] Evidence Summary: - Primary study: [Citation] - Design: [RCT / Observational / Meta-analysis] - Sample size: n = [X] - Results: [Primary outcome with effect size, CI, p-value] - Quality assessment: [Strengths and limitations] Benefits: - [Quantified benefit 1] - [Quantified benefit 2] Harms: - [Quantified harm 1] - [Quantified harm 2] Balance: [Benefits clearly outweigh harms / Close balance requiring discussion / etc.] Values and Preferences: [Little variability / Substantial variability] Cost Considerations: [If relevant] Guideline Concordance: - NCCN: [Category and recommendation] - ASCO: [Recommendation] - ESMO: [Grade and recommendation] ``` ## Quality Checklist Before finalizing recommendations, verify: - [ ] Recommendation statement is clear and actionable - [ ] Strength is explicitly stated (strong vs conditional) - [ ] Quality of evidence is graded (high/moderate/low/very low) - [ ] GRADE notation provided (1A, 1B, 2A, 2B, 2C) - [ ] Evidence is cited with specific study results - [ ] Benefits are quantified (effect sizes with CIs) - [ ] Harms are quantified (AE rates) - [ ] Balance of benefits/harms is explained - [ ] Patient values consideration is addressed (if conditional) - [ ] Alternative options are mentioned - [ ] Guideline concordance is documented - [ ] Special populations are addressed (elderly, renal/hepatic impairment) - [ ] Monitoring requirements are specified